Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioMarin Pharmaceutical Inc. BMRN
$93.47
-$1.88 (-2.01%)
На 18:00, 12 мая 2023
+27.08%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
17568812851.00000000
-
week52high
117.77
-
week52low
70.73
-
Revenue
2096039000
-
P/E TTM
252
-
Beta
0.38442900
-
EPS
0.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 09 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 04 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 04 авг 2022 г. |
| Barclays | Overweight | Overweight | 04 авг 2022 г. |
| Cantor Fitzgerald | Overweight | 13 июл 2022 г. | |
| RBC Capital | Sector Perform | Sector Perform | 13 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 13 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 27 окт 2022 г. |
| Credit Suisse | Outperform | Outperform | 27 окт 2022 г. |
| JP Morgan | Overweight | Overweight | 24 окт 2022 г. |
| Oppenheimer | Outperform | Perform | 31 окт 2022 г. |
| Jefferies | Buy | Buy | 29 ноя 2022 г. |
| Canaccord Genuity | Hold | 18 янв 2023 г. | |
| Wedbush | Neutral | Neutral | 11 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 03 февр 2023 г. |
| BMO Capital | Market Perform | 30 янв 2023 г. | |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ajer Jeffrey Robert | D | 0 | 46800 | 25 янв 2023 г. |
| Ajer Jeffrey Robert | D | 41088 | 4175 | 25 янв 2023 г. |
| Ajer Jeffrey Robert | D | 45263 | 44825 | 25 янв 2023 г. |
| Ajer Jeffrey Robert | A | 90088 | 49000 | 25 янв 2023 г. |
| BIENAIME JEAN JACQUES | D | 193130 | 10000 | 17 янв 2023 г. |
| BIENAIME JEAN JACQUES | D | 320424 | 10000 | 17 янв 2023 г. |
| BIENAIME JEAN JACQUES | A | 330424 | 10000 | 17 янв 2023 г. |
| BIENAIME JEAN JACQUES | D | 203130 | 10000 | 13 янв 2023 г. |
| BIENAIME JEAN JACQUES | D | 320424 | 10000 | 13 янв 2023 г. |
| BIENAIME JEAN JACQUES | A | 330424 | 10000 | 13 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5094810 | -48386 | 31 авг 2020 г. |
| Vanguard Mid-Cap Index Fund | 4438720 | -33356 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 2567770 | -15136 | 31 июл 2020 г. |
| American Funds AMCAP Fund | 10517700 | 0 | 30 июн 2020 г. |
| American Funds Growth Fund of America | 8495430 | 0 | 30 июн 2020 г. |
| Vanguard PRIMECAP Fund | 6013300 | 69000 | 30 июн 2020 г. |
| Vanguard Capital Opportunity Fund | 5245030 | 900 | 30 июн 2020 г. |
| Harbor Capital Appreciation Fund | 2346970 | -115282 | 30 июн 2020 г. |
| Dodge & Cox Stock Fund | 2326320 | -195000 | 30 июн 2020 г. |
| American Funds New World Fund | 2221210 | 224534 | 30 июн 2020 г. |
Новостная лента
New Strong Sell Stocks for May 1st
Zacks Investment Research
01 мая 2023 г. в 06:51
AOMR, BMRN and CUTR have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2023.
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
Zacks Investment Research
27 апр 2023 г. в 12:10
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.
BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research
26 апр 2023 г. в 21:16
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
26 апр 2023 г. в 18:59
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.55 per share a year ago.
7 Biotech Stocks That Could Cure Your Portfolio Woes
InvestorPlace
19 апр 2023 г. в 19:22
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).